 |
|
Ovarian function and fertility preserved in women with severe systemic lupus erythematosus
June 13, 2008Ovarian function can be preserved and disease activity controlled in women with severe systemic lupus erythematosus (SLE) when treated with a 6-month course of cyclophosphamide (CYC), a chemotherapy drug, followed by the immunosuppressant mycophenolate mofetil (MMF), according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
SLE, a complex and unpredictable autoimmune disease, is characterised by chronic inflammation and damage of body tissues, including the heart, lungs, kidneys, joints, and/or nervous system. It is most common in women and, although long-term survival has dramatically improved over time with better diagnosis and treatment options, one of the challenges in managing the disease is to minimise the side-effects of treatments such as the disruption of ovarian function and risks to fertility. Pulsed intravenous CYC, a chemotherapeutic agent, is a standard therapy for SLE but may also be associated with ovarian failure in addition to other adverse effects.
Dr Katerina Laskari, the presenting author of the study, led by Professor Athanasios G Tzioufas in the Department of Pathophysiology of the National and Kapodistrian University of Athens, said: "Although the prognosis for people with SLE has considerably improved over the years, a patient's quality of life can all too often be seriously impaired by the toxicity of many commonly-used treatments. Preserving ovarian function is a very important consideration in treating women with SLE of child-bearing age, who are already burdened by the difficult nature and impact of the disease itself."
In this retrospective evaluation of 61 postmenopausal women with SLE treated for lupus nephritis (n=58), autoimmune hemolytic anemia (n=1) and central nervous system involvement (n=2), 39 patients received prolonged treatment with 1g/m2 intravenous (IV) CYC pulses (group A) for a median time of 24 months and 22 patients received 5-7 monthly 1g/m2 IV CYC pulses, followed by 2g/day MMF for a median time of 32 months (group B).
Results showed that disease activity was equally controlled using either treatment regimen (p=0.76 and p=0.31 for disease remission and relapse respectively), although patients in group A had a 4-fold higher risk of developing amenorrhea (absence of menstruation) compared with those in group B (p=0.001). 56% (n=22) of women in group A and 14% (n=3) in group B developed amenorrhea, while sustained amenorrhea developed in 51% (n=20/39) of women in group A vs 4% (n=1) in group B. 14% (3/22) of women in group A and 67% (2/3) in group B resumed menstruation following cessation of therapy.
Age (p<0.001), cumulative CYC dose (p=0.001) and anti-Ro antibodies (p=0.002) were significant in terms of amenorrhea. Sustained amenorrhea was related to both the form of treatment (p=0.006) and the age of the patients (p=0.026). The median total CYC dose until amenorrhea was 11 gr (range 2-29.5) and 3.7 gr (range 2-6.75) in group A and B respectively (p=0.036).
The median age of women with amenorrhea was 36 years (range 19-46) in group A and 33 years (range 27-45) in group B (p=0.71). It is of note that all patients aged >31 years developed amenorrhea with the long course CYC treatment and 94% did not resume menses until the end of follow up, whereas only 1 patient aged 45 years developed permanent amenorrhea with the short course CYC treatment.
SLE disease duration and ECLAM (European Consensus Lupus Activity Measurement) score were not significantly different in terms of amenorrhea (p≥0.05).
European League Against Rheumatism
In this retrospective evaluation of 61 postmenopausal women with SLE treated for lupus nephritis (n=58), autoimmune hemolytic anemia (n=1) and central nervous system involvement (n=2), 39 patients received prolonged treatment with 1g/m2 intravenous (IV) CYC pulses (group A) for a median time of 24 months and 22 patients received 5-7 monthly 1g/m2 IV CYC pulses, followed by 2g/day MMF for a median time of 32 months (group B).
Results showed that disease activity was equally controlled using either treatment regimen (p=0.76 and p=0.31 for disease remission and relapse respectively), although patients in group A had a 4-fold higher risk of developing amenorrhea (absence of menstruation) compared with those in group B (p=0.001). 56% (n=22) of women in group A and 14% (n=3) in group B developed amenorrhea, while sustained amenorrhea developed in 51% (n=20/39) of women in group A vs 4% (n=1) in group B. 14% (3/22) of women in group A and 67% (2/3) in group B resumed menstruation following cessation of therapy.
Age (p<0.001), cumulative CYC dose (p=0.001) and anti-Ro antibodies (p=0.002) were significant in terms of amenorrhea. Sustained amenorrhea was related to both the form of treatment (p=0.006) and the age of the patients (p=0.026). The median total CYC dose until amenorrhea was 11 gr (range 2-29.5) and 3.7 gr (range 2-6.75) in group A and B respectively (p=0.036).
The median age of women with amenorrhea was 36 years (range 19-46) in group A and 33 years (range 27-45) in group B (p=0.71). It is of note that all patients aged >31 years developed amenorrhea with the long course CYC treatment and 94% did not resume menses until the end of follow up, whereas only 1 patient aged 45 years developed permanent amenorrhea with the short course CYC treatment.
SLE disease duration and ECLAM (European Consensus Lupus Activity Measurement) score were not significantly different in terms of amenorrhea (p≥0.05).
European League Against Rheumatism
Lupus Erythematosus News and Current Lupus Erythematosus Events RSSAccumulated bits of a cell's own DNA can trigger autoimmune disease
A security system wired within every cell to detect the presence of rogue viral DNA can sometimes go awry, triggering an autoimmune response to single-stranded bits of the cell's own DNA, according to a report in the August 22nd issue of the journal Cell, a Cell Press publication.
'Multi-target' immune therapy improves outcomes of severe lupus nephritis
A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a report in the October Journal of the American Society of Nephrology (JASN).
Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases
The TRAF1/C5 locus on chromosome 9 has been revealed to play a role in multiple autoimmune diseases including type 1 diabetes and systemic lupus erythematosus (SLE).
Lupus more severe in patients with Southern European ancestry
ystemic lupus erythematosus (SLE) patients with a higher percentage of ancestry from southern Europe have more severe disease manifestations, according to new research presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
Abnormal 'editing' of gene messages may be a cause of lupus
Researchers at Wake Forest University have uncovered evidence that the abnormal "editing" of gene messages in a type of white blood cell may be behind the development of lupus.
Several genes that regulate the disease SLE have been identified
Swedish researchers, in collaboration with foreign colleagues, have identified a number of new genes that can be tied to the disease SLE, including a gene that hopefully might be used to treat the disease in the future by regulating the production of antibodies.
DNA variations signal lupus risk
Scientists have pinpointed a set of common variations in human DNA that signal a higher risk for lupus in women who carry them.
NEJM editorial on significance and limitations of new lupus gene expression research
Some 1.5 million Americans, most of them women, suffer from lupus, a disease where the person's immune system attacks the body's own tissue.
Genes linked with lupus are revealed, giving hope for new treatments
Scientists have identified a number of genes involved in Lupus, a devastating autoimmune disease, in new research published today in the journal Nature Genetics.
Scientists identify genes linked to lupus in women
An international consortium of scientists has identified multiple genes that are linked to systemic lupus erythematosus, a devastating autoimmune disease that affects between 1 million and 2 million Americans.
More Lupus Erythematosus News Articles
 | The Lupus Book: A Guide for Patients and Their Families by Daniel J Wallace. Lupus, a disease of the immune system, can be quite deadly, claiming the lives of thousands of patients yearly. Dr. Daniel J. Wallace is one of the world's leading authorities on this disorder, an eminent clinician who has treated over 2000 lupus patients, the largest such practice in America. His The Lupus Book, originally published in 1995, immediately established itself as the most readable... |
 | The First Year--Lupus: An Essential Guide for the Newly Diagnosed by Nancy C. Hanger Lupus affects an estimated 1.5 million people in the U.S.—90 percent of whom are women—but due to the diversity of its symptoms and severity, it remains one of the most difficult conditions to identify and diagnose. In the tradition of the other titles in the First Year™ series, The First Year™—Lupus uses a unique approach—guiding readers through their first... |
 | Lupus: Alternative Therapies That Work by Sharon Moore A comprehensive guide to noninvasive, nontoxic therapies for lupus--written by a lupus survivor. • The only book to focus on alternative therapies for lupus.• Includes therapeutic approaches drawn from the fields of naturopathic medicine, nutritional medicine, environmental medicine, traditional Chinese medicine, nontoxic dentistry, energy medicine, and psychological... |
 | New Hope for People with Lupus: Your Friendly, Authoritive Guide to the Latest in Traditional and Complementary Solutions by Theresa Foy Digeronimo, Sara J. Henry Discover Exciting New Ways to Manage LupusNow you can take control of lupus and begin living a healthier, better life—today! This thoughtful, cutting-edge book can help you manage the flare-ups, symptoms, and side effects of lupus and put you back on the path to a more enjoyable, active lifesyle. Inside is compassionate, practical, and immediate guidance for anyone affected by lupus,... |
 | Lupus Handbook for Women: Up-to-Date Information on Understanding and Managing the Disease Which Affects by Robin Dibner A complete Guide for Women with LupusThe Lupus Handbook for women provides all the information a woman needs to understand the disease, its diagnosis, and the treatment. It will answer her questions and help her to work with her doctor in managing the disease.Rheumatologist Dr. Robin J. Dibner, in clear and supportive terms, tells women what they need to know, including:* What lupus is, how it... |
 | Positive Options for Living with Lupus: Self-Help and Treatment (Positive Options) by Philippa Pigache The effects of lupus — a difficult-to-diagnose condition in which the immune system attacks the body — can be mild or life threatening. Therapy and awareness of lupus have improved greatly in recent years, and this book contains the latest information about the disease, its diagnosis, and its cures. The book covers different types of lupus; self-care and when to call the doctor; lupus... |
 | Living with Lupus: The Complete Guide, Second Edition by Sheldon Paul Blau, Dodi Schultz An estimated 1.4 million Americans, most of them women, suffer from lupus, a chronic auto-immune disease in which the immune system attacks the body. With symptoms ranging from skin rashes to kidney dysfunction, lupus is a complicated and frustrating disease, the cause of which is still unknown.In the newly revised Living with Lupus, Dr. Sheldon Blau helps patients, their caregivers, and their... |
 | Dubois' Lupus Erythematosus Established for forty years as the definitive reference on lupus, Dubois' Lupus Erythematosus is now in its thoroughly revised, updated Seventh Edition. More than ninety distinguished contributing authors--twenty of them new to this edition--provide comprehensive coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical... |
 | Connective Tissue Diseases: Holistic Therapy Options--Sjoegren¿s Syndrome; Systemic Sclerosis - Scleroderma; Systemic Lupus Erythematosus; Discoid Lupus Erythematosus; Secondary and Primary Raynaud¿s phenomenon; Raynaud¿s Disease; Polymyositis ¿ Dermatomyositis by Hannelore Helbing-Sheafe Hannelore Helbing-Sheafe’s constant struggle with her health was a powerful motivator to investigate possible ways to help herself and others. The focus of her practice was always on finding the cause of the problem and instructing patients in using correct nutrients and/or natural medicine and therapy to correct and reverse existing health problems. Her main focus has been to seek... |
 | Lupus Underground: A Patient's Case for a Long-Ignored, Drug-Free, Non-Patentable, Counter-Intuitive Therapy That Actually Works - UVA1 Phototherapy by Anthony DeBartolo A Chicago reporter suddenly stricken with lupus gives himself the assignment of finding a way back on his feet. After spending nearly two and a half years researching and exactly $4,934.48 on tanning equipment (that's right, sun tanning equipment), he files this report on a long-ignored, drug-free, non-patentable, counter-intuitive therapy that actually worked - UVA1... |
| © 2008 BrightSurf.com |